Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Revenues came in $614.58 million, which grew 1.2% from the year-ago quarter and 4.7% sequentially. The figure surpassed the Zacks Consensus Estimate of $590 million.

The top line was driven by robust performance of network solution segment of the company. Further, strong customer demand remained a major positive. Additionally, strengthening supply chain environment contributed to the first-quarter results.

Product and services revenues accounted for 88.7% and 11.3% of total revenues. While product revenues improved 1.4% from the year-ago quarter, services revenues declined 0.5%.

Following the better-than-expected first-quarter results, shares of the company have risen 21.4%. Coming to one year price performance, shares of Itron have lost 3.5% against the industry’s rally of 11.6%.

The company’s bookings were $473 million, down 15.1% year over year. The company’s backlog came in at $3 billion, decreasing 3.2%, year over year. Further, its 12-month backlog came in at $1.4 billion, which remained flat year over year.

Device Solutions: The company generated $221.8 million revenues (36.1% of total revenues) from this segment, down 11.1% from the year-ago quarter. This was primarily owing to decline in the EMEA volumes during the reported quarter. Further, operating margin within this segment contracted 380 bps year over year. Nevertheless, the company witnessed improvement in supply chain scenario and enhanced performance by book and ship business.

Networked Solutions: Revenues from this segment came in $336.4 million (54.7% of total revenues), increased 11.3% year over year. This was driven by growing customer deployments and robust performance in North America AMI market. Notably, operating margin expanded 190 bps year over year on the back of benefits from integration synergies.

Outcomes: This segment generated $56.4 million revenues (9.2% of total revenues), up 1.6% on a year-over-year basis. The company witnessed strengthening recurring managed service offerings and persistent growth in North America deployments, which in turn drove the segment’s top line. Further, operating margin came in 18.5% against a loss of 1.2% in the year-ago quarter. This can be attributed to benefits from Silver Spring Networks buyout and favorable product mix.

For the first quarter, Itron’s gross margin was 30.5%, which expanded 90 bps from the prior-year quarter. This can be attributed to favorable product mix and robust higher-margin software sales.

Non-GAAP operating expenses were $130.6 million, down 14.1% year over year. This decrease resulted from strong restructuring and integration initiatives.

Non-GAAP operating margin came in 9.2%, expanding significantly 460 bps from the year-ago quarter. This was driven by robust Networked Solutions and Outcomes segments.

Balance Sheet and Cash Flows

As of Mar 31, 2019, cash and cash equivalents totaled $110.8 million compared with $120.2 million as of Dec 31, 2018. Accounts receivables were $473.1 million, increasing from $437.2 million in the previous quarter.

Itron generated $24.9 million cash from operations compared with $42.4 million generated in the previous quarter.

Moreover, the company generated free cash flow of $13.5 million, up from $24.9 million in prior quarter.

Guidance

For second-quarter 2019, management expects earnings and revenues to be flat or slightly down on a sequential basis.

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

Resources

Client Support

Follow Us

Zacks Mobile App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.08% per year. These returns cover a period from January 1, 1988 through March 4, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.